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ABSTRACT  
There are limited data on the outcomes of pancreas transplants using ABO non-
identical but compatible (NIC) donors. 
Methods: A review of all pancreas transplants from a single institution from 01/2003 
to 07/2016 (n=606) revealed 41 recipients of a NIC donor pancreas which were 
matched for age, race, gender, year and type of transplant with 41 ABO identical 
cases. Groups were compared for allograft survival, incidence of acute cellular 
rejection (ACR), length of hospital stay, 3-month readmissions and transfusion 
requirements. Serum haptoglobin and Lactate dehydrogenase were used to identify 
hemolysis in patients requiring repeated transfusions without overt blood loss. 
Results: The 1-year graft survival was 100% and 88% in the study and control 
groups. In the study group, 6/41(14%) developed hemolysis, all of which were ABO 
O into A. All responded to donor blood type specific transfusions. Discussion: There 
are limited data on outcomes of solid organ transplant using NIC donors with almost 
none specifically addressing pancreas transplantation. In this study, graft survival 
was similar but 14% developed hemolysis, which was transient and treated with 
transfusion of donor blood type specific blood. Conclusion: NIC pancreas 
transplants have similar graft survival compared to ABO identical. Hemolysis may 
occur so some caution is required. 
KEY WORDS
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INTRODUCTION 
Pancreas transplantation is an established treatment option for patients with type 1 
diabetes mellitus (T1D) as well as select patients with type 2 diabetes mellitus. In the 
United States, 1.25 million people have T1D including about 200,000 youth (< 20 
years old) and over a million adults (> 20 years old) 1. Despite the high prevalence of 
T1D and improving transplant outcomes, the number of pancreas transplants have 
declined over the last decade2-4. In the year 2016, only 1013 pancreas allografts 
were transplanted (798 simultaneous kidney and pancreas (SPK) and 215 isolated 
pancreas transplants), which is down from a peak of 1484 pancreas transplants in 
2004. This represents a 32% decrease5.  
The ABO blood group is the most important of all the blood group systems.  There 
are four different ABO blood groups (see Table1), determined by whether or not an 
individual's cells carry the A antigen, the B antigen, both A and B antigens (AB) or 
neither (O). Normal healthy individuals, from early in childhood, develop antibodies 
against A or B antigens that are not expressed on their own cells. Recipients may 
receive organs from donors with the same or compatible blood types, meaning to 
which they do not have preexisting antibodies. Additionally, there are also potentially 
compatible combinations that involve the donor blood type A2 and there are 
instances where incompatible transplants are acceptable, but this is beyond the 
scope of this report.  
There are numerous studies describing utilization of ABO non-identical but 
compatible (NIC) donors for heart 6, 7 and lung transplantation8,9. Most of these 
studies have shown no statistically significant difference in long term graft survival 
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among identical and NIC transplants. There are emerging studies  regarding 
intestine transplantation that may suggest that NIC intestine/multi-visceral 
transplants may have higher rates of rejection10. Kim et al reported comparable
outcomes for ABO NIC and identical liver transplants11. Numerous reports have been 
published documenting hemolysis in NIC liver, kidney and intestine transplants12-14. 
However, there is no data on the outcomes of pancreas transplants using NIC 
donors except for a single case report of passenger lymphocyte syndrome after SPK 
transplantation15. Currently, the United Network for Organ Sharing (UNOS) / Organ 
Procurement and Transplantation Network (OPTN) policy is to only allocate SPK 
allografts according to certain compatible blood types (Table 2). Specifically, blood 
type O donors are only shared with NIC donors in situations where the recipient is 
highly sensitized (calculated panel reactive antibody (CPRA) ≥80%) and has a zero 
antigen human leukocyte antigen (HLA) mismatch. Similarly, blood group B donor 
organs are exclusively shared with ABO identical recipients. Note again that these 
policies apply exclusively to SPK allocation, with broader sharing across all 
compatible ABO groups for isolated pancreas transplants such as pancreas after 
kidney (PAK) and pancreas transplant alone (PTA), but currently the vast majority of 
pancreas transplants performed in the United States are SPKs. These combinations 
were intended to mirror kidney allocation, where there is such a significant 
discrepancy between number of candidates waiting and number of organs available 
that certain blood types and demographics would be significantly disadvantaged if 
these limits were not set. For pancreas transplantation, however, where the volumes 
are small and decreasing, it is unfortunate when there are situations where a 
pancreas allograft could be transplanted if a suitable recipient were identified but yet 
the donor organ is wasted. In fact, OPTN policy 5.4.E “Allocation to Candidates Not 
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on the Match Run” specifically addresses allocating an organ to a recipient that is not 
on the match run (as would be the case for many NIC donors) in order to avoid 
wasting a donor organ (in this case the pancreas). Nonetheless, this is contrary to 
the existing SPK allocation policy, which would require modification. Broader use of 
blood group NIC pancreas allografts may encourage local use of SPK allografts, 
which is currently the single best opportunity to place a pancreas allograft, and may 
lead to greater utilization of this scarce and underutilized resource. The goal of this 
study was to retrospectively review a single center’s experience with NIC donors 
specifically to ensure the safety of this approach as the community moves toward 
embracing broader allocation of pancreas allografts across compatible ABO blood 
types.   
 
Materials and methods 
A retrospective analysis of medical record data at a single institution from January 
2003 to July 2016 revealed a total of 606 recipients of a SPK, PAK or PTA.  Inclusion 
criteria for the study were all candidates aged more than 18 years old who received 
a pancreas transplant from a NIC ABO blood group donor. The analysis revealed 41 
recipients of a NIC donor pancreas. They were matched for demographic variables 
such as age, race, gender, year of transplant and type of transplant with 41 ABO 
identical pancreas transplants.  
 
A review of medical history revealed that 4 patients had hypothyroidism, 3 had 
rheumatoid arthritis and 2 were on anticoagulation for hyper-coagulable states in the 
study group. In the control group, 3 patients had hypothyroidism, 1 had Grave’s 
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disease and 2 were on anticoagulation for hyper-coagulable state and atrial 
fibrillation. However, none had any past medical history of hemolytic diseases. 
 
Donor organs were procured in a standard fashion as described previously16. The 
recipient operation was performed through a midline incision. The pancreas was 
routinely positioned with the tail toward the pelvis and the head and duodenum 
oriented superiorly in order to facilitate the enteric anastomosis. Systemic venous 
drainage was performed to the right common iliac vein or to the vena cava. Arterial 
perfusion of the allograft was routinely established from the right common iliac artery. 
All pancreas allografts were drained enterically using a stapled technique as 
described elsewhere17. For SPK, the pancreas and kidney were typically placed 
ipsilaterally on the right side as described elsewhere18. 
 
The immunosuppression protocol consisted of induction with rabbit anti-
thymocyte globulin (rATG) (5 mg/kg total dose) along with a single dose of rituximab 
(150 mg/m2) and maintenance with tacrolimus (target trough 6-8 ng/ml) and sirolimus 
(target trough 3-6 ng/ml) for SPK and PAK with addition of mycophenolate mofetil 
500 mg bid for PTA. Steroids were exclusively used as a premedication for rATG 
and were discontinued following induction in all recipients. All recipients received 
routine perioperative antibiotics, prophylaxis against cytomegalovirus with oral 
valgancyclovir and prophylaxis against Pneumocystis jiroveci pneumonia with 
trimethoprim and sulfamethoxazole, unless contraindicated. Systemic 
anticoagulation was not routinely used unless the patient had a specific history of a 
coagulation disorder.  
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Demographic and immunologic data collected included age, race, gender, HLA 
mismatch, class I, class II panel reactive antibody levels and CPRA level. The 
primary outcome for the study was blood product requirement for both cases and 
controls within the first year of transplant. The two groups were compared for 
secondary outcomes such as incidence of acute cellular rejection (ACR); length of 
hospital stay after transplant; number of readmissions within 3 months of transplant 
and projected 5year graft survival by Kaplan Meier analysis. Acute cellular rejection 
was diagnosed based on clinical presentation of elevated serum lipase and 
treatment included steroid boluses +/- rATG. Serum haptoglobin level, lactate 
dehydrogenase (LDH) and direct Coomb’s test were used to identify hemolysis in 
patients needing repeated transfusions without overt blood loss.  
Retrospective analysis of data on transplant patients at our center was reviewed and 
approved by the institutional review board. Statistical testing was performed on 
statistical software for the social sciences (IBM SPSS Statistics, IBM Corporation, 
Armonk, NY). 
RESULTS 
The data was available for all patients in the study and control groups. The minimum 
follow up was 6 months. There were 41 recipients of a NIC pancreas transplant. Of 
these, 13 received an SPK,14 PAK and 14 PTA.  These were matched for age, race, 
gender, year of transplant and type of transplant with 41 ABO identical pancreas 
transplants. 
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The median age of the recipient was 43 years in the study group and 46 years in the 
control group with 44% males and 56% females in both cohorts. 95% of patients in 
the control group and 98% in the study group were Caucasian. The two groups were 
comparable for years of diabetes prior to transplant (29 years in the study group and 
31 years in the control group) and body mass index (24.9kg/m2 in the study group 
and 24.8 kg/m2 in the control group). Patients were comparable for immunologic 
matching with a median of 4HLA antigen mismatch in both groups and median 
CPRA of 76% in study versus 83% in control group (Table 3). Three out of the 41 in 
the study group had a zero antigen mismatch. Of the 3, only one had a CPRA >80%. 
One patient in the study group had a positive T-cell cross-match with no donor 
specific antibody on high definition assay whilst no one had a positive B-cell cross-
match in either of the groups. 
 
In the study group, 3 patients had heparin related bleeding in the early post-
operative period. One patient had Parvo B19 virus associated anemia and another 
patient developed gastrointestinal bleeding on post-operative day 6.  One patient in 
the control group had an acute gastrointestinal bleed several weeks prior to the 
transplant. There was no statistically significant difference in the pre-operative 
hemoglobin (Hb) between the study group (Median Hb 12.4g/dl, mean±SD 12.7±2.1 
g/dl) and controls (Median Hb 12.2g/dl, mean±SD 12.3±21.6 g/dl) (p value=0.10). 
 
The mean number of units of packed red blood cell (PRBC) transfusions in the first 
year of transplant in the study group was 5.8 units, compared to 4.5 units in the 
control group (p>0.05). Six of 41 patients (14%) in the study group had hemolysis as 
evidenced by elevated LDH, decreased haptoglobin level and a positive Coomb’s 
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test. All of these were donor blood type O into recipient blood type A transplants. 
Within the study group the mean number of units of transfused PRBCs within the 1st 
year for those with evidence of hemolysis was 9.3 and for those without hemolysis 
was 4.9 units. (p value =0.7) The patients with hemolysis did require more PRBC 
transfusions; however the small sample size limits us from drawing any significant 
conclusions from the data. None of the patients in the control group had any 
evidence of hemolysis or a positive Coomb’s test during the duration of the study.  
 
The average length of hospital stay after transplant was 8 days in the study group 
and 6.5 days in the control group (p>0.05). The rate of re-admission to hospital 
within the first 3 months after transplant was 55% and 40% in study and control 
groups (p>0.05). There was 1 case of ACR in the control group while none were 
seen in the study group (Table 4). The median 1 year graft survival by Kaplan-Meier 
was 100% in the study group and 88% in the control group (p<0.05). (Fig 1) 
 
DISCUSSION 
 
There are variable data on outcomes for liver, kidney, heart, lung and intestine 
transplantation using NIC donors6-14. There is, however, no data regarding pancreas 
transplantation using NIC donors. Currently the UNOS pancreas transplant 
committee is investigating options to allow broader allocation of ABO NIC SPK 
transplantation. Currently, the allocation system allows for blood group O donor 
organs to be utilized for blood group A, B or AB recipients only if the recipient has a 
zero antigen HLA mismatch and a CPRA greater than or equal to 80 percent and 
sharing of blood group A (but not B) donors for AB recipients. Additionally, the UNOS 
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pancreas committee recently identified an error in allocation programming which has 
since been corrected that allowed sharing of blood group B donors with AB 
recipients. It was in discussing this issue, and specifically the pancreas allografts that 
were transplanted in this setting that otherwise would likely have been wasted, that 
the concept of eliminating all ABO barriers to pancreas transplantation was brought 
up. This limitation was, after all, not based on any medical or clinical concerns for 
recipient outcome. Our study had patients who were not zero antigen mismatches 
and/or CPRA >80%. The long-term outcomes were comparable between the control 
and the study groups. This study, however, is limited by the relatively small size of 
the patient population and by the study design of a single center retrospective study. 
Nonetheless, this may be considered as a proof of principle and an initial step in 
considering pancreas transplantation across blood types outside of the current 
OPTN guidelines. Utilization of O donors for A, B or AB recipients could theoretically 
put patients with blood type O listed for a kidney alone at a disadvantage by taking a 
kidney away from the donor pool. However, SPK recipients are legitimately kidney 
transplant candidates with identical listing criteria to those on the isolated kidney 
transplant waiting list. This is in contrast to other combinations of kidney transplant 
with extra-renal organs where these criteria do not need to be met. The waiting list 
mortality rate is highest for SPK candidates as compared to kidney alone listed 
patients for other indications19. Patients listed for SPK also have been shown to have 
higher life years from transplant (LYFT) than kidney recipients20. Thus, utilization of 
pancreas and kidney transplantation for this patient population can be considered as 
an optimal utilization of a limited resource. 
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Allo-immune mediated hemolysis (AIH) is a known phenomenon in NIC stem cell 
and solid organ transplantation and is caused by donor derived lymphocytes 
producing antibodies against recipient blood group antigens21, 22. The risk for 
developing hemolysis is greatest for the ABO group O into A combination21. 
Antibodies against minor blood group antigens like Rhesus and Lewis antigens can 
also cause hemolysis23-25. Clinically significant hemolysis requiring blood 
transfusions has been reported to occur in about 70%, 40% and 17% in ABO NCI 
heart-lung, liver and kidney transplants respectively21, 23. The hemolysis is usually 
transient, occurring within the first 3 months after transplant, and can be treated with 
monitoring and transfusion of donor blood type specific PRBCs. Rarely, additional 
immunosuppression like corticosteroids, rituximab, immunoglobulin (IVIG) or 
plasmapheresis may be required14. In some instances, severe hemolysis can cause 
disseminated intravascular coagulation leading to organ failure and mortality. In our 
series, 14% of pancreas transplants manifested signs of hemolysis. All of these 
recipients were of blood type A and received blood type O donor organs. The 
hemolysis rate was less in this series when compared to other solid organ transplant 
recipients. The induction protocol with rATG and rituximab may have played a role in 
the incidence of hemolysis in this series. rATG usage for induction 
immunosuppression has been reported to cause a myriad of reactions including 
cytokine release syndrome, neutropenia, thrombocytopenia, hemolytic anemia and 
serum sickness26. Anemia may occur through different mechanisms in this setting 
including hemolysis, bonemarrow suppression or immune dysregulation.  None of 
the patients needed additional therapies other than PRBC transfusions and the 
transfusion requirements for the identical ABO and the NIC ABO groups were 
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comparable. This may suggest that transplant across blood types is likely safe 
outside of the current immunological guidelines for organ allocation. 
 
CONCLUSION: ABO compatible and ABO identical pancreas transplants have 
similar outcomes even when organs are used without a zero antigen mismatch or a 
CPRA > 80%. AIH may occur after such transplants and is frequently self-limited and 
can be managed with donor type specific blood transfusion and monitoring.  
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ABBREVIATIONS 
ACR = acute cellular rejection  
CPRA = calculated panel reactive antibody 
HLA = human leukocyte antigen 
LDH = lactate dehydrogenase 
NIC = ABO non-identical but compatible  
PAK = pancreas after kidney transplant 
PRBC = packed red blood cells 
PTA = pancreas transplant alone 
rATG = rabbit anti-thymocyte globulin 
SPK = simultaneous kidney and pancreas transplant 
T1D = type 1 diabetes mellitus 
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Table 1. ABO blood group antigen and antibody distribution in blood 
Blood Type Antibodies in circulation Compatible blood type 
O Anti-A, anti-B, anti AB O 
A Anti-B A, O 
B Anti-A B, O 
AB None AB, A, B, O 
 
 
 
Table 2. Allocation of Kidney-pancreas by blood type 
Donor blood type Blood type of the eligible candidates 
O O or Blood type A, B or AB if the candidate 
has a zero antigen mismatch with the 
donor and a CPRA ≥80% 
A A or AB 
B B 
AB AB 
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Table 3. Comparison of demographics and immunologic data for matched  
ABO identical and ABO compatible pancreas transplant patients. 
  
ABO 
identical 
ABO 
compatible, 
not ABO 
identical 
p-
value 
OVERALL (number) 41 41 
Recipient demographics 
Years of diabetes (mean, median) 31 29 0.22 
Gender: Male (percent) 44% 44% 1.00 
Race: White (percent) 95% 98% 1.00 
Age (years, median(range)) 46 43 0.69 
Body mass index (median) 24.8 24.9 0.86 
Transplant type 
Simultaneous pancreas and kidney 32% 32% 1.00 
Pancreas after previous kidney 34% 34% 
Pancreas transplant alone 34% 34% 
Immunologic matching 
Class I panel reactive antibody: 0% 88% 78% 0.15 
Class II panel reactive antibody: 0% 88% 93% 0.25 
Calculated panel reactive antibody: percent 0% 83% 76% 0.48 
T-cell crossmatch positive 0% 2% (1) 1.00 
B-cell crossmatch positive 0% 0% 1.00 
Human leucocyte antigen mismatch: median 
number (mean) 4 (4.2) 4 (3.9) 0.40 
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Table 4. Comparison of clinical outcome measures for matched ABO compatible  
and ABO identical pancreas transplant patients . 
  
ABO 
identical 
ABO 
compatible, 
not ABO 
identical 
p-
value 
n=41 n=41 
Clinical outcomes 
Acute cellular rejection within first year 1 (2.4%) 0 (0%) 1.00 
Length of hospital stay (days) 6.5 8 0.69 
Any readmission within 3 months 40% 55% 0.34 
Peak post-transplant amylase 220 241 0.61 
Peak post-transplant lipase 138 135 0.65 
Transfusion requirement (mean, median) 
Packed red cells intraoperative 0.4, 0 0.5, 0 0.74 
Packed red cells (first year) 4.5, 2 5.8, 4 0.54 
Fresh frozen plasma (first year) 0.4, 0 1.3, 0 0.36 
Platelets (first year) 0.2, 0 0, 0 0.10 
1-year graft survival 88% 100% 0.05 
Median survival by Kaplan-Meier (months) 110 119 0.27 
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Figure 1. 5 year survival for matched ABO compatible and identical donor 
pancreas transplant recipients. 
